OPEN ACCESS Freely available online

ISSN: 2167-7956
Journal of Biomolecular Research & Therapeutics

Commentary

Current Advances in Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma

Shirley Paul*

Department of Biomolecules, University of York, York, England

DESCRIPTION

As a very heterogeneous cancer subtype, renal cell carcinoma can effectively resist the immune system due to the complex microenvironment of the tumour. Current research focuses mainly on the key complex of histocompatibility, immunotherapeutic cells, produced immunosuppression cytokines, and oxidative stress molecule signal transmission in order to understand the molecular pathways of immune escape in renal cell carcinoma. For patients with metastatic or advanced renal cell carcinoma, immunotherapy is the best treatment choice and combination immunotherapy for the practical application of effective medicines thorough in-depth understanding of the molecular basis of immune escape in renal cell carcinoma. In ordinary situations, the immunological system helps the body fight tumours [1]. If the immune system's involvement in monitoring is diminished, malignant tumours may grow which calls for a variety of immune evasion techniques. The immune surveillance theory put forth by Burnet gave rise to tumour immune escape. They contend that the body's immune system will regulate mutant "non-self" cells that can be specifically destroyed to maintain the integrity of the microenvironment of the body. However, the tumour will continue to grow and degenerate if mutant cells manage to escape immune system surveillance as a result of numerous internal or external stimuli. Immunological elimination, immune balance and immune escape are the three mechanisms that make up tumour immune escape. The fact that many tumours continue to develop in the body and even cause host death despite the immune system of the body producing some anti-tumor immune response suggests that the tumour may somehow evade the host immune system or prevent the body from producing an effective anti-tumor immune response. The majority of cancers can form or spread through the immune system's control, which makes it impossible to separate immunological escape from immune development [2]. Changes in tumour auto antigenicity and a complex immunological microenvironment create ideal circumstances for tumour immune escape in the case of exceedingly diverse malignancies like RCC. Unique molecular mechanisms include the following features: anomaly in the way the antigen is delivered and in the processing systems. Autoimmune escape strategies for renal cell cancer, including MHC, immunosuppression cells and their produced immunosuppressive cytokines and cell signaling of apoptotic molecules, have been investigated in recent years as the molecular biology of renal cell carcinoma advances. It is particularly concerning since the immunological milieu of the tumour significantly influences immune escape, yet the immune microenvironment is exceedingly complicated and constantly changing, so focusing on one of these components can result in chain changes [3]. This entails the coordinated action of several factors to change the tumor's immunosuppressive microenvironment in order to accomplish the goal of destroying or even eliminating the tumour. The clinical efficiency of RCC therapy has significantly increased from the time of systemic cytokine administration to the time of targeted medications and then to the time of immunotherapy as a result of the identification of the immune escapes mechanisms of renal cell carcinoma [4]. Renal cell carcinoma phase III immunotherapy-based clinical trials and the results of ongoing trials will be used to determine how RCC care is likely to change in the future. Immunotherapy is anticipated to significantly improve patient survival rates in the future and decrease the occurrence of adverse events by administering fewer doses of medication. A crucial component of RCC treatment is new immunotherapy. The selection of immunotherapeutic targets for patients is also crucial and even when using the same target, different people may respond differently to the same medication. Patients with renal cell carcinoma would receive various types of treatments to the opening of the precision medical model and the development of personalized treatment plans, increasing clinical effectiveness. Therefore, preclinical studies and animal models are crucial for improving RCC immunotherapy [5]. Future research may examine molecular markers that regulate immune effectiveness to guide the therapy of renal cell carcinoma.

Correspondence to: Shirley Paul, Department of Biomolecules, University of York, York, England, E-mail: paul@gmail.com

Received: 02-Sep-2022, Manuscript No. BOM-22-18350; **Editor assigned:** 05-Sep-2022, Pre QC No. BOM-22-18350(PQ); **Reviewed:** 19-Sep-2022, QC No. BOM-22-18350; **Revised:** 26-Sep-2022, Manuscript No. BOM-22-18350(R); **Published:** 03-Oct-2022, DOI: 10.35248/2167-7956.22.11.233.

Citation: Paul S (2022) Current Advances in Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma. J Biol Res Ther. 11:233.

REFERENCES

1. Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, et al. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI insight. 2018; 3(24).
2. Klümper N, Ralser DJ, Bawden EG, Landsberg J, Zarbl R, Kristiansen G, et al. LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. J Immunother Cancer. 2020; 8(1).
3. McKay RR, Bossé D, Xie W, Wankowicz SA, Flaifel A, Brandao R, et al. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell CarcinomaPD-1/PD-L1 Inhibition in Non–Clear Cell Renal Cell Carcinoma. Cancer Immunol Res. 2018; 6(7):758-765.
4. Klaver Y, Kunert A, Sleijfer S, Debets R, Lamers CH. Adoptive T-cell therapy: a need for standard immune monitoring. Immunotherapy. 2015; 7(5):513-533.
5. Lamers CH, Klaver Y, Gratama JW, Sleijfer S, Debets R. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells–a completed study overview. Biochemical society transactions. 2016; 44(3):951-959.